Stockreport

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Catar...

Harrow, Inc.  (HROW) 
Last harrow, inc. earnings: 11/13 04:21 pm Check Earnings Report
PDF MELT-300 Demonstrates Statistically Superior Compared to Both Sublingual Midazolam (P=0.009) and Placebo (PProportion of Patients Requiring Rescue Sedation Was Nearly Tw [Read more]